“INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM): A BOON TO FUTURE”
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 3256-3264
AbstractBackground: Postpartum anemia imposes a disproportionately substantial disease burden during a critical period of maternal-infant interaction. Postpartum anemia requires prevention and treatment not only for that particular period but also to ensure good health with enough iron stores at the start of the next pregnancy. Among various parenteral iron preparations, single-dose intravenous (FCM) ferric carboxymaltose is more effective to cure anemia.
Material & Methods:
This was an observational prospective interventional study in 120 anemic postnatal women in Government Medical College, Akola- Maharashtra. Patients with Hb <10 grams were assigned to this study and were given intravenous FCM. Data were collected and statistical analysis was performed. Treatment potency was assessed through repeat hemoglobin (Hb) and ferritin titers which indicate the iron (Fe) stores. Drug safety was assessed by the evaluation of drug reactions.
A significant rise in Hb, MCV, and ferritin levels was observed after 1 week and 1 month after receiving Inj.FCM. The mean change in the hemoglobin levels were 0.845 and 2.405 on day 7 and at day 28 respectively. Mean changes in the MCV levels were 3.06 and 6.42 on day 7 and on day 28 respectively. The mean change in the Sr. Ferritin levels was 102.56 ng / ml on day 28. This means the change in the Sr. Ferritin level was statistically significant with a ‘P’ value < 0.0001.
Intravenous ferric carboxymaltose is an efficacious and safe drug to treat postpartum anemia in women of reproductive age.
- Article View: 5
- PDF Download: 13